Serum fibroblast growth factor-21 levels and its relationship with carotid intima-media thickness in type 1 diabetes mellitus patients

Year 2024, Volume: 37 Issue: 1, 67 - 71, 28.01.2024

Hatice Çalışkan , Mehmet Yaşar , Dilek Yazıcı , Oğuzhan Deyneli

https://doi.org/10.5472/marumj.1381672

Abstract

Objective: The study aimed to evaluate fibroblast growth factor-21 levels in type 1 diabetes patients and its relationship with carotid
intima-media thickness which is a marker of atherosclerosis.
Patients and Methods: We recruited 39 patients with type 1 diabetes mellitus and 39 healthy controls. Blood samples for fibroblast
growth factor-21, adiponectin and carboxymethyllysine were drawn from subjects after 8 hours fasting. Fasting blood glucose and
hemoglobinA1c levels were obtained from patient records. Carotid intima media-thickness was measured via B-mode ultrasound by
the same physician.
Results: Median fibroblast growth factor-21 levels were 0.54 (0.10-10.69) ng/ml in type 1 diabetes patients, 0.42 (0.09-1.57) ng/ml
in healthy controls (P=0.13). There was no correlation between serum fibroblast growth factor-21 levels and carotid intima-media
thickness. Carboxymethyllysine levels were similar in both groups (P=0.86). Adiponectin level was 16336.7 ± 7338.7 ng/ml in type 1
diabetes patients, 13343.1 ± 5318.7 ng/ml in control group (P=0.04).
Conclusion: Our study did not find any relation between serum fibroblast growth factor-21 levels and carotid intima-media thickness.
Further researches with wider study population are needed.

Keywords

fibroblast growth factor-21, carotid intima-media thickness, type 1 diabetes mellitus

References

• Powers, AC. Diabetes Mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. New York: The McGraw-Hill Companies, 2012:2968-69.
• Fleir JS. Hormone resistance in diabetes and obesity: insulin, Leptin, and FGF21. Yale J Biol Med.Yale 2012; 85:405-14.
• Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246- 53. doi: 10.2337/db07-1476.
• Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gammaglutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94:2151-6. doi: 10.1210/jc.2008-2331
• Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53:934- 40. Doi: 10.1016/j.jhep.2010.05.018
• Xiao Y, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 2012; 97:54-8. doi: 10.1210/jc.2011-1930
• Zibar K, Blaslov K, Bulum T, Ćuća JK, Smirčić-Duvnjak L. Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine 2015; 48:848-55. doi: 10.1007/ s12020.014.0413-9
• Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high resolution B-mode imaging. Diabetes 1994; 43:634-9. doi: 10.2337/diab.43.5.634
• Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236:567-73. doi: 10.1111/j.1365-2796.1994.tb00847.x.
• Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-35. doi: 10.1210/ jcem.86.5.7463.
• Imagava A, Funahashi T, Nakamura T, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-6. doi: 10.2337/diacare.25.9.1665
• Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-9. doi: 10.1161/01. atv.000.004.8856.22331.50.
• Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Informa Healthcare 2002;11:1205-23. doi: 10.1117/1.JBO.22.8.085003
• Wautier MP, Massin P, Guillausseau PJ, et al. N(carboxymethyl) lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes and Metab 2003; 29:44–52. doi: 10.1016/s1262-3636(07)70006-x.
• Taniguchi H, Nirengi S, Ishihara K, Sakane N. Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus. PLoS One 2022;17:e0263774. doi: 10.1371/journal.pone.0263774.
• Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J. The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci 2018;14:1000-11. doi: 10.7150/ijbs.25026.
• Bayir O, Korkmaz HA, Dizdarer C, Meşe T, Tavli V. Carotid artery intima-media thickness in pediatric type 1 diabetic patients. Anadolu Kardiyol Derg 2014; 14:464-70. doi: 10.5152/akd.2014.4788.
• Järvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002; 51:493-8. doi: 10.2337/diabetes.51.2.493
• Rabago Rodriguez R, Gómez-Díaz RA, Tanus Haj J, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30:2599-602. doi: 10.2337/dc07-0922.
• Wang X, Huang X, Hou J. Relationship between Serum fibroblast growth factor 21 levels and morphological atherosclerotic plaque characteristics in patients with coronary heart disease. Eur Heart J Suppl 2016;18(Suppl F): F37. doi: 10.1093/eurheartj/suw036
• Xiao Y, Liu L, Xu A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14:72. doi: 10.1093/ eurheartj/suw036
• Maahs DM, Ogden LG, Snell-Bergeon JK, et al. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol 2007; 166:731-40. doi: 10.1093/aje/ kwm125
• Ljubic S, Boras J, Jazbec A, et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32:271-9. Doi: 10.25011/cim.v32i4.6618
• Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005; 48:1911-8. doi: 10.1007/s00125.005.1850-z.
• Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond.) 2002; 103:137-42. doi: 10.1042/cs1030137
• Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 2003; 46:459-69. doi: 10.1007/ s00125.003.1074-z
• Hwang JS, Shin CH, Yang SW. Clinical implications of Nε- (carboxymethyl) lysine, advanced glycation end product, in children and adolescents with type 1diabetes. Diabetes Obes Metab 2005;7:263-67. doi: 10.1111/j.1463-1326.2004.00398.x